Delapril

Summary

Delapril (CHEMBL589583) is a phase-3 clinical-stage small molecule (ATC C09AA12); indicated across 2 conditions including cardiovascular disorder and hypertensive disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: C09AA12
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 452.5 Da · C26H32N2O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL589583
Name	Delapril
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5362116
ATC	C09AA12
Molecular formula	C26H32N2O5
Molecular weight	452.5
InChIKey	WOUOLAUOZXOLJQ-MBSDFSHPSA-N

SMILES: CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N(CC(=O)O)C2CC3=CC=CC=C3C2

IUPAC name: 2-[2,3-dihydro-1H-inden-2-yl-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]amino]acetic acid

Also known as: Delapril, DELAPRIL, delapril, Delapril HCl

Parent form; salt/anhydrous children: CHEMBL2106126

Patent coverage: 3,199 distinct patent families (13,765 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	3	MONDO:0004995	EFO:0000319
hypertensive disorder	3	MONDO:0005044	EFO:0000537

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00157586	PHASE3	COMPLETED	Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).